Abstract: The present disclosure relates generally to methods and protocols for the diagnosis, prognosis and stratification of patients with, or at risk of developing, sporadic amyotrophic lateral sclerosis (ALS). In particular, the methods and protocols of the present disclosure are based on determination of the presence and number of cytosine (C) adenine (A) dinucleotide repeats (CA dinucleotides) within the STMN2 gene.

Abstract: The invention relates in general to hydrophilic, biocompatible dendronised polymers, to complexes comprising the dendronised polymers, to methods of preparing the dendronised polymer and to uses of the dendronised polymer as a non-viral transfection agent for the delivery of biomolecules, in particular, genome editing tools, into a cell.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Abstract: A multiphase flow metering device may have a conduit through which a multiphase fluid can flow and a structured packing insert positioned in the conduit. The structured packing insert may have a water-wet packing structure zone and/or an oil-wet packing structure zone. The multiphase flow metering device may also have a Halbach pre-polarizing magnet array positioned around the conduit, an RF coil, an electromagnet, an NMR console adapted to detect NMR signals from the multiphase fluid, and a control system configured to vary a polarization of the Halbach pre-polarizing magnet array. The Halbach pre-polarizing magnet array may be positioned or positionable over one or both of the oil-wet and water-wet packing structure zones. In some embodiments, the structured packing insert may include immobilized radicals, providing for dynamic nuclear polarization of the multiphase fluid.

Abstract: A multiphase flow metering device may have a conduit through which a multiphase fluid can flow and a structured packing insert positioned in the conduit. The structured packing insert may have a water-wet packing structure zone and/or an oil-wet packing structure zone. The multiphase flow metering device may also have a Halbach pre-polarizing magnet array positioned around the conduit, an RF coil, an electromagnet, an NMR console adapted to detect NMR signals from the multiphase fluid, and a control system configured to vary a polarization of the Halbach pre-polarizing magnet array. The Halbach pre-polarizing magnet array may be positioned or positionable over one or both of the oil-wet and water-wet packing structure zones. In some embodiments, the structured packing insert may include immobilized radicals, providing for dynamic nuclear polarization of the multiphase fluid.

Abstract: An isolated or purified antisense oligomer for modifying RNA cleavage and processing in the NEAT1 gene transcript or part thereof.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Abstract: An apparatus to directly detect solids formation in a fluid under known pressure and temperature conditions is disclosed. The apparatus includes a vessel having an electromagnetic resonant cavity defined by an upper portion, a lower portion and a gap defined therebetween, the gap having resonant properties sensitive to the presence of a solid phase therein. The upper portion or the lower portion may be provided with a passage extending therethrough in fluid communication with an inlet to allow ingress of a stream of fluid to the gap and thereby purge solids from the cavity subsequent to solids formation. The apparatus also includes one or more probes, one or more sensors and a signal processor operatively connected to said sensors and said one or more probes to directly detect solids formation in the fluid within the cavity in response to detected changes in the resonant properties of the cavity.

Abstract: This invention relates to a chocolate or chocolate substitute composition or product comprising (a) at least compound to be delivered to a subject; (b) a chocolate or chocolate substitute matrix and at least (i) a masking agent or (ii) a firming agent, wherein the composition or product is substantially stable.

Abstract: Provided herein are biomolecule conjugates, and methods of use thereof, wherein the conjugate comprises a cytokine, typically an immunopotentiating cytokine, and a peptide comprising or consisting of the sequence CSGRRSSKC (SEQ ID NO:1). Biomolecule conjugates of the invention find application, inter alia, in the treatment of tumours, atherosclerosis and fibrosis, and the degradation of ECM associated therewith. Also provided herein are uses of a peptide comprising or consisting of the sequence of SEQ ID NO:1, optionally linked to a detectable agent and/or a carrier, in the detection and/or localisation of tumour, atherosclerotic and fibrotic tissue.

Abstract: A method for characterising a mechanical property of a material. The method comprises the steps of providing the material having a deformable portion and providing a device having an optical element that is arranged to detect electromagnetic radiation.

Abstract: This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.

Abstract: The present invention relates to the delivery of oligomers for treating patients with a 5? mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5? mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Abstract: A sensing element (10) for an intrinsic gravity gradiometer (IGG) for use in sensing variation in a gravity field at a location. The sensing element (10) is flexible, elongate and has unfixed opposed ends (12, 14) when part of the gravity gradiometer. The sensing element can be a metallic ribbon, and can be mounted by a number e.g. 3 or 5, pivot points or axes 30-40 at each of the opposed sides along the sensing element, with the opposed ends of the sensing element free to move. The pivot points or axes can include pins, preferably cylindrical pins (48) or the sensing element may be etched within the side wall and remain joined to the remainder of the side wall by connections. The sensing element (10) can form part of one or more resonant cavities or wave guide (44, 52-66), such as a side or dividing wall (46) or part thereof. A dual phase bridge (61,612) arrangement can be provided. Electrical current (I) can be injected into the sensing element.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.

Abstract: A method of outputting a warning indicative of potential migraine onset includes controlling a display of an electronic device to display, to a user, test stimuli of at least one spatial visual contextual test that is a perceptual analogue of centre-surround neuronal responses in human vision, and receiving, via an input device of the electronic device, at least one response of the user to the test stimuli. The method also includes processing the at least one response of the user to obtain test outcome data, and outputting a warning indication of potential migraine onset to the user if the test outcome data is outside an expected range for daily fluctuation in test outcome data.

Abstract: A system (10) for indicating the likelihood of a gastrointestinal (GI) condition by analysing bowel sounds is provided, the system (10) comprising a sound detector (12) configured to detect bowel sounds and generate a corresponding signal representative of the bowel sounds, a signal processor arranged to identify a plurality of bowel sound signals within the corresponding signal, each bowel sound signal representative of an individual bowel sound, wherein the system is arranged to identify at least one feature from each of the plurality of bowel sound signals so as to produce a collection of values for the same at least one feature, and determine at least one statistical distribution property of the collection of values, the statistical distribution property capable of at least assisting in providing an indication of the existence or non-existence of a GI condition, and wherein the system is further arranged to associate the at least one statistical distribution property with a reference parameter and determi

Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.